BiotechTube

Roxadustat

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia Associated With End Stage Renal Disease (ESRD)

Conditions

Anemia Associated With End Stage Renal Disease (ESRD)

Trial Timeline

May 26, 2020 → Oct 11, 2021

NCT ID
NCT04410198

About Roxadustat

Roxadustat is a phase 3 stage product being developed by AstraZeneca for Anemia Associated With End Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT04410198. Target conditions include Anemia Associated With End Stage Renal Disease (ESRD).

What happened to similar drugs?

20 of 20 similar drugs in Anemia Associated With End Stage Renal Disease (ESRD) were approved

Approved (20) Terminated (5) Active (0)
✅Aranesp®AmgenApproved
✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved
✅Epoetin AlfaJohnson & JohnsonApproved
✅Roxadustat + rHuEPOAstraZenecaApproved
✅ICL670 + Chelation + No chelationNovartisApproved
✅cera, darbepoetin, epoetin-beta + ESARocheApproved
✅methoxy polyethylene glycol-epoetin beta [Mircera]RocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04621331Phase 3Withdrawn
NCT04484857Phase 3Completed
NCT04410198Phase 3Completed

Competing Products

20 competing products in Anemia Associated With End Stage Renal Disease (ESRD)

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40